REG - Ergomed plc - Award of Share Options

ErgomedAnnouncement

30/01/2020 07:01

RNS Number : 3627B
Ergomed plc
30 January 2020
 


 PRESS RELEASE
 
 
Ergomed Award of Share Options
 
Guildford, UK - 30 January 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Incentive Plan) awards have been made to recently appointed Chief Operating Officer, Lewis Cameron.
On 29 January 2020, Mr Cameron was awarded a total of 250,000 share options over the Company's ordinary shares, having a nominal value of 1 pence each, with an exercise price of 1 pence per share (the "Options"). Of the total, 125,000 will vest three years after the commencement of Mr Cameron's employment with the Company and are not subject to performance criteria. The remaining 125,000 are subject to performance criteria and will vest dependent on total shareholder return of 15% per annum over three years.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 
 



1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Lewis Cameron




2


Reason for the notification




a)


Position/status


Chief Operating Officer and Director




b)


Initial notification /Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Ergomed Plc




b)


Legal Entity Identifier


213800BVS8I9VMC1AP84




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary shares of 1 pence each
 
 
 GB00BN7ZCY67




b)


Nature of the transaction


Grant of options under the Company's Long Term Incentive Plan




c)


Currency


GBP




d)


Price(s) and volume(s)


Price(s)


Volume(s)




1 pence


250,000














e)


Aggregated information
- Aggregated volume
- Price
- Aggregated total


250,000 ordinary shares at an exercise price of 1 pence per share.




f)


Date of the transaction


29 January 2020




g)


Place of the transaction


Outside a trading venue.



 
ENDS
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Richard Barfield (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Sue Stuart


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser

















 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFFFEFLFIAFII